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A review of patients with skull base osteosarcoma secondary to radiation (radiation-induced osteosarcoma: RIOS) of
the pituitary tumor shows the mean survival of approximately 7 months (2 weeks – 16 months). This warning
prognosis seems to stem from two factors, 1) the anatomical complexity of the skull base for total resection of the
tumor, and 2) standard adjuvant therapies for the tumor yet to be established. Contrary to the general belief, the
authors report an unusually long survival of a 75-year-old woman with a history of osteosarcoma that developed in
the same sequence 20 years after pituitary tumor radiation. On her recent admission, she complained of frontal
headaches and MRI studies showed a tumor in the sphenoid sinus. Endoscopic trans-nasal tumor removal allowed
for histological diagnosis of an osteosarcoma. However, further rapid tumor growth necessitated a radical tumor
resection followed by a combined chemotherapy with ifosfamide, cisplatin, and etoposide (ICE). Despite temporary
suppression of the tumor growth, the chemotherapy was discontinued due to severe pancytopenia that occurred
after three courses of treatment. Shortly after the discontinuation of ICE therapy, the tumor size increased again
rapidly, requiring a novel radiation therapy, Cyber-knife treatment. Following this radiation, the tumor growth was
arrested, and the patient remains healthy without neurological symptoms over 24 months. The outcome of
Cyber-knife in this case suggests that this specific therapy must be considered for the unresectable skull base RIOS.
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The incidence of radiation-induced osteosarcoma (RIOS)
is from 0.01% to 0.03% of all irradiated patients [1,2],
and accounts for 5.5% of all osteosarcomas [2]. Histolo-
gically, RIOS is characterized by more aggressive fea-
tures than primary osteosarcoma [3,4]. Particularly in
craniofacial osteosarcomas, the 5-year survival rate is
70% in primary osteosarcomas and 17% in RIOS [5,6].
This discrepancy in prognosis reflects the difficulty in
total resection of the latter, because of its anatomical
features. As a contrast, we present a case of skull base
RIOS in a patient with much longer survival than any
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In November 2009, a 75-year-old Asian woman pre-
sented with a chief complaint of severe frontal head-
aches for several weeks. The history dated back to 20
years earlier when she underwent subtotal resection of a
nonfunctioning pituitary adenoma, followed by irradi-
ation (50 Gy). Magnetic resonance imaging (MRI)
showed an enhanced mass that filled the entire sphenoid
sinus cavity, farther invading both cavernous sinuses
without involvement of the pituitary gland and stalk
(Figure 1A white arrow). Subtotal resection of a whitish,
elastic, and easily bleeding tumor was performed by
trans-nasal endoscopic approach (Figure 1B black
arrow). There was no tumor invasion seen in the dura
through the defective floor of the sella (Figure 1B black
arrowhead). Postoperatively, a residual tumor was noted
in both cavernous sinuses (Figure 1C white arrowheads).
The patient was free of headaches after surgery and was
discharged to home in December 2009. The tumor wasl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Before and after the first tumor resection. A. MRI
shows an enhanced mass in the sphenoid sinus. The tumor extends
into both cavernous sinuses surrounding internal carotid arteries.
The pituitary gland and stalk are clearly identified (white arrow), and
there is no tumor invasion in the sellaturcica. B. The photo shows a
trans-nasal endoscopic view of the tumor. The anterior wall of
sphenoid sinus is absent, and a whitish tumor (black arrow) is seen
through the nasal cavity. The tumor was elastic and bled easily.
There is no tumor invasion in the dura mater in the sellaturcica
(black arrowhead). C. The tumor in the sphenoid sinus was totally
removed; however, residual tumor is noted in cavernous sinuses
(white arrowheads).
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with high cellularity and pleomorphism, mixed with
osteoid osseous component (Figure 2A-a). Vimentin was
strongly positive (Figure 2A-b), while anti-cytokeratin
(CAM 5.2) was negative (Figure 2A-c). Ki-67 scoring
(MIB-1 index) was extremely high at 20% (Figure 2A-d),
corresponding to the diagnosis. These findings are
clearly different from those of the previously resected pi-
tuitary adenoma (Figure 2B).
In March 2010, the patient returned to clinic, com-
plaining of stuffy nose. Follow-up MRI demonstrated ex-
tensive regrowth of the tumor in the nasal cavity
(Figure 3A). In April, a second subtotal trans-nasal endo-
scopic tumor resection was performed without extending
to the cavernous sinus portion (Figure 3B). Several
courses of chemotherapy started immediately with ifosfa-
mide, cisplatin, and etoposide (ICE) at 2-month intervals,but was discontinued one month after the third course
due to severe pancytopenia (white blood cell 400/mm3,
platelet <10,000/mm3) associated with malaise. Although
a few doses of granulocyte-colony stimulating factor
(GCSF: Lenograstim) effectively ameliorated mild pan-
cytopenia after the first and second chemotherapy, the
severe pancytopenia developed after the third chemo-
therapy, and was not adequately controlled by several
administrations of GCSF.
In January 2011, she was noted to have right visual
impairment with optic atrophy, only light perception
preserved. MRI showed tumor extension into the eth-
moid and sphenoid sinuses, and the right optic canal
(Figure 4A). In February, the third subtotal trans-nasal
endoscopic tumor removal was performed, leaving the
portion attached to the walls of ethmoid and sphenoid
sinuses, and in the cavernous sinus intact (Figure 4B).
In the end of the month, Cyber-knife radiation was
delivered to the residual tumor in five fractions. Target
volume was 11716 mm3, collimator was 20 mm in
diameter, marginal dose was 39.38 Gy, and side dose
was 55.71 Gy. In September 2011, MRI showed no far-
ther tumor regrowth in the entire area of radiation
(Figure 4C, Table 1). She lives at home and continues to
be asymptomatic for 24 months since the first surgery.
Discussion and conclusions
In 1948, Cahan et al. described the following conditions
as a definition of the radiation-induced sarcoma: 1) the
initial and secondary neoplasms are of significantly dif-
ferent histological type; 2) the secondary neoplasm must
arise within the irradiated area; 3) there must be a long
latency period after radiation (>5 years); and 4) all sarco-
mas must be proven histologically [7]. Our case fulfilled
all these four conditions, and the diagnosis of RIOS was
established. The most frequent radiation-induced sar-
coma is fibrosarcoma, and osteosarcoma is extremely
rare [8,9]. Based on our review of seven reports, the me-
dian survival time of skull base RIOS is 7 months (range
2 weeks to 16 months). The main causes of the early
death after surgery were bleeding from the tumor or in-
ternal carotid artery (ICA), and occlusion of ICA. Fatal
ICA damage can be attributed to aggressive tumor re-
moval in the cavernous sinus. Although some reports
described the effectiveness of chemotherapy using
methotrexate, ifosfamide, doxorubicin, carboplatin, vin-
cristine, or etoposide, their results are variable [10-12],
and a definite protocol has not been established. In the
presence of uncontrollable rapid regrowth of the intra-
cranial RIOS, which are known to be resistant to any type
of treatment, we selected Cyber-knife irradiation as a
novel treatment. This radiation method has three advan-
tages over others: 1) it utilizes its ability to be focused on
the target, using the multi-angled planes. Therefore, the
Figure 2 Histological findings. A: a. Hematoxylin and eosin staining shows condensed tumor cells with pleomorphism, and depositions of
osseous tissue are recognized. b. Vimentin was strongly positive. c. Anti-cytokeratin (CAM 5.2) staining is negative, indicative of no malignancy of
squamous epithelium. d. Ki-67 scoring (MIB-1 index) is extremely high at 20%. B: The tumor tissue, resected from the patient 20 years ago,
consists of typical pituitary adenoma cells, which are entirely different from the pathological features identified in A.
Figure 3 Recurrence of the tumor. A. Four months after the first surgery, MRI demonstrates rapid regrowth of the tumor filling sphenoid and
ethmoid sinuses and nasal cavity. B. A residual tumor is seen in the cavernous sinuses after massive tumor resection.
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Figure 4 After chemotherapy and cyber-knife treatment. A. Tumor regrowth is noted after discontinuation of ICE chemotherapy on MRI. B.
The cavernous sinus portion of the tumor is noted after the third tumor resection. C. No obvious tumor recurrence is identified seven months
after cyber-knife radiation.
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which provides the radiation energy only in the single
plane, 2) the sizes of tumors of irregular shapes can be
evaluated by CT or MRI during Cyber-knife treatment,
and radiation doses can be adjusted to maximize the ra-
diation effects. Since the tumor of our patient extended
into the cavernous sinus, and different air sinuses, three
dimensional evaluation can be done during treatment, 3)
Cyber-knife does not require cumbersome equipment as
proton beam and gamma knife treatment. In the litera-
ture, no report on Cyber-knife treatment is found toTable 1 Review of skull base radiation-induced osteosarcoma




Amine & Sugar (1976) [13] 16 F pituitary adenoma 51.0
Tanaka et al. (1989) [14] 57 M craniopharyngioma 110.0
Salvati et al. (1994) [15] 45 M pituitary adenoma 44.0
Gnanalingham et al. (2002) [8] 67 F pituitary adenoma 52.2
Hansen et al. (2003) [16] 29 M pituitary adenoma 52.0
Bembo et al. (2004) [17] 45 M pituitary adenoma 46.8
Patel et al. (2011) [18] 44 F craniopharyngioma 60.0
Present case 75 F pituitary adenoma 50.0demonstrate its effectiveness on RIOS. Our patient’s re-
markable daily activity speaks itself for the control of
RIOS regrowth by Cyber-knife. We present a case of
skull base RIOS with an exceptionally long survival by a
combination of endoscopic resection and cyber-knife
radiation.Consent
Written informed consent was obtained from the patient






10 sella radiation 5 weeks
15 sphenoid wing embolization surgery 2 weeks
12 sphenoid radiation (50 Gy) 16 months
14 sella surgery -
22 sella–clivus surgery (short)
5 sella surgery 7 weeks
9 sphenoid–ethmoid sinus chemotherapy 16 months
20 sphenoid sinus surgery chemotherapy
cyber-knife
24 months ~
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view by the Editor-in-Chief of this journal.
Abbreviations
RIOS: Radiation-induced osteosarcoma; ICE: Ifosfamide, cisplatin, and
etoposide; MRI: Magnetic resonance imaging.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
Guarantor of the integrity of the study: SMY. Study concepts: SMY and AM.
Study design: SMY. Definition of intellectual content: SK and SK. Literature
research: SMY and SY. Clinical studies: YI and SY. Data acquisition: SMY. Data
analysis: SMY, YI, and AM. Statistical analysis: SK and SK. Manuscript
preparation: SMY. Manuscript review: AM. All authors read and approved the
final manuscript. Manuscript English language editing: JAM Post, Inc.
Source of funding
The authors have no funding declared.
Author details
1Department of Neurosurgery, Teikyo University Chiba Medical Center,
3426-3 Anesaki, Ichihara, Chiba 299-0111, Japan. 2Department of
Neurosurgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo
113-8603, Japan. 3Department of Radiology, Nippon Medical School, 1-1-5
Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Received: 28 March 2012 Accepted: 7 July 2012
Published: 10 August 2012
References
1. Goodman MA, McMaster JH: Primary osteosarcoma of the skull. Clin
Orthop Relat Res 1976, 120:110–114.
2. Salvati M, Ciappetta P, Raco A: Osteosarcomas of the skull. Clinical
remarks on 19 cases. Cancer 1993, 71:2210–2216.
3. Robinson E, Neugut AI, Wylie P: Clinical aspects of postirradiation
sarcomas. J Natl Cancer Inst 1988, 80:233–240.
4. McHugh JB, Thomas DG, Herman JM, Ray ME, Baker LH, Adsay NV, Rabah R,
Lucas DR: Primary versus radiation-associated craniofacial osteosarcoma:
biologic and clinicopathologic comparisons. Cancer 2006, 107:554–562.
5. Patel SG, Meyers P, Huvos AG, Wolden S, Singh B, Shaha AR, Boyle JO,
Pfister D, Shah JP, Kraus DH: Improved outcomes in patients with
osteogenic sarcoma of the head and neck. Cancer 2002, 95:1495–1503.
6. Chabchoub I, Gharbi O, Remadi S, Limem S, Trabelsi A, Hochlef M, Ben
Fatma L, Landolsi A, Mokni M, Kraiem C, Ben Ahmed S: Postirradiation
osteosarcoma of the maxilla: a case report and current review of
literature. J Oncol 2009, 2009:876138.
7. Cahan WG, Woodward HQ, Higinbotham NL, Stewart FW, Coley BL:
Sarcoma arising in irradiated bone: report of 11 cases. Cancer 1948,
1:3–29.
8. Gnanalingham KK, Chakraborty A, Galloway M, Revesz T, Powell M:
Osteosarcoma and fibrosarcoma caused by postoperative radiotherapy
for a pituitary adenoma. Case report. J Neurosurg 2002, 96:960–963.
9. Berkmann S, Tolnay M, Hänggi D, Ghaffari A, Gratzl O: Sarcoma of the sella
after radiotherapy for pituitary adenoma. Acta Neurochir (Wien) 2010,
152:1725–1735.
10. Wiklund TA, Blomqvist CP, Raty J, Elomaa I, Rissanen P, Miettinen M:
Postirradiation Sarcoma. Analysis of a nationwide cancer registry
material. Cancer 1991, 68:524–531.
11. Sugita Y, Shigemori M, Miyagi J, Ochiai S, Lee S, Watanabe T, Abe H,
Morimatsu M: Radiation-induced osteosarcoma of the calvaria—case
report. Neurol Med Chir (Tokyo) 1992, 32:32–35. Review.
12. Carpentier AF, Chantelard JV, Henin D, Poisson M: Osteosarcoma following
radiation treatment for meningioma: report of a case and effective
treatment with chemotherapy. J Neurooncol 1994, 21:249–253.
13. Amine AR, Sugar O: Suprasellar osteogenic sarcoma following radiation
for pituitary adenoma. Case report. J Neurosurg 1976, 44:88–91.
14. Tanaka S, Nishio S, Morioka T, Fukui M, Kitamura K, Hikita K: Radiation-
induced osteosarcoma of the sphenoid bone. Neurosurgery 1989,
25:640–643.15. Salvati M, Cervoni L, Ciappetta P, Raco A: Radiation-induced
osteosarcomas of the skull: report of two cases and review of the
literature. Clin Neurol Neurosurg 1994, 96:226–229.
16. Hansen MR, Moffat JC: Osteosarcoma of the skull base after radiation
therapy in a patient with McCune-Albright Syndrome: case report. Skull
Base 2003, 13:79–83.
17. Bembo SA, Pasmantier R, Davis RP, Xiong Z, Weiss TE: Osteogenic sarcoma
of the sella after radiation treatment of a pituitary adenoma. Endocr Pract
2004, 10:335–338.
18. Patel AJ, Rao VY, Fox BD, Suki D, Wildrick DM, Sawaya R, DeMonte F:
Radiation-induced osteosarcomas of the calvarium and skull base.
Cancer 2011, 117:2120–2126.
doi:10.1186/1748-717X-7-136
Cite this article as: Yamada et al.: Advanced therapeutic strategy for
radiation-induced osteosarcoma in the skull base: a case report and
review. Radiation Oncology 2012 7:136.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
